MedTrace Logo

A SAD Study of ZT002 Injection in Healthy Participants

NCT06423872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-05-21

No results posted yet for this study

Summary

This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.

Conditions

Interventions

DRUG

ZT002

Participants will receive a single subcutaneous (SC) ZT002 injection.

OTHER

Placebo

Participants will receive same volume as of the study drug.

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • Beijing QL Biopharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Aixin Shi, Master · No.1 Dahua Road, Dongdan, Dongcheng District, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2023-10-20
Completion
2023-12-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06423872 on ClinicalTrials.gov